THERAPEUTICS
Methylnaltrexone reduced opioid-induced constipation in patients with terminal illness
| The first 150 words of the full text of this article appear below. |
J Thomas
Dr J Thomas, San Diego Hospice and Palliative Care, San Diego, CA, USA; jthomas@sdhospice.org
STUDY DESIGN
randomised placebo controlled trial.
unclear allocation concealment.*
blinded (patients, healthcare providers, and outcome assessors).*
STUDY QUESTION
27 nursing homes, hospice sites, and palliative care centres in the USA and Canada.
133 patients
18 years of age (median age 71 y, 57% women) who had terminal illness with life expectancy
1 month, were receiving opioids for analgesia, and had opioid-induced constipation (<3 laxations in the previous wk or no laxation in the previous 48 h, despite having taken laxatives for
3 d).
subcutaneous methylnaltrexone, 0.15 mg/kg body weight (n = 62), or placebo (n = 71) every other day for 2 weeks. Laxatives could be taken as needed but not within 4 hours of the study drug.
rescue-free laxation within 4 hours after the first dose and within 4 hours after
2 of the first 4 doses,
Mayo Clinic, Rochester, Minnesota, USA
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
